PD-1 inhibitors can effectively block the binding of T cells to the tumor cell immune checkpoint PD-1/PD-L1 by competing for newly binding PD-1 receptors located on the surface of T cells to reactivate the immunotoxic function of T cells and generate positive antitumor effects. Here, CD274 is linked to neoplasm.